From the U.S. perspective, the November elections may have a profound impact on these laws. Potential changes include revised patent litigation venue rules, increased restrictions on “pay-for-delay” patent settlements, revised antitrust enforcement priorities, laws targeted at speeding drug and medical device approval, and revisions to the Affordable Care Act. There is great uncertainty about the direction of these and other relevant laws under the new administration and Congress.